Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06793709
A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy
Sponsor: Eisai Co., Ltd.
View on ClinicalTrials.gov
Summary
The primary purpose of this study is to investigate the safety of Tasfygo.
Official title: Post-marketing Observational Study of Tasfygo Tablet 35 mg to Evaluate the Safety of Tasfygo in Patients With Unresectable Biliary Tract Cancer With FGFR2 Fusion Gene Positivity Who Progressed After Chemotherapy
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
60
Start Date
2025-07-10
Completion Date
2032-11-20
Last Updated
2026-02-27
Healthy Volunteers
No
Conditions
Interventions
OTHER
No Intervention
This is a non-interventional study.
Locations (1)
#Eisai Trial Site 1
Tokyo, Japan